A single-dose pharmacokinetic study of emamectin benzoate in cod, Gadus morhua L., held in sea water at 9 degrees C.
The pharmacokinetic profile of the antiparasitic agent emamectin benzoate was studied in plasma after intravenous (i.v.) injection and in plasma, muscle and skin following oral (p.o.) administration to cod, Gadus morhua, held in sea water at 9 degrees C and weighing 100-200 g. Following i.v. injection, the plasma drug concentration-time profile showed two distinct phases. The plasma distribution half-life (t(1/2)alpha) was estimated as 2.5 h, the elimination half-life (t(1/2)beta) as 216 h, the total body clearance (Cl(T)) as 0.0059 L kg(-1) h(-1) and mean residence time (MRT) as 385 h. The volume of distribution at steady state, V(d(ss)), was calculated to be 1.839 L kg(-1). Following p.o. administration the peak plasma concentration (C(max)) was 15 ng mL(-1), the time to peak plasma concentration (T(max)) was 89 h and t(1/2)beta was 180 h. The highest concentration in muscle (21 ng g(-1)) was measured after 7 days and t(1/2)beta was calculated to be 247 h. For skin, a peak concentration of 28 ng g(-1) at 3 days was observed and a t(1/2)beta of 235 h was determined. The bioavailability following p.o. administration was calculated to be 38%.
Samuelsen
O B
OB
Institute of Marine Research, Nordnes, Bergen, Norway. ole.samuelsen@imr.no
D000818:Animals; D000977:Antiparasitic Agents / Q000493:pharmacokinetics*; D001682:Biological Availability; D003080:Cold Temperature; D048389:Gadus morhua / Q000378:metabolism*; D006207:Half-Life; D007559:Ivermectin / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D009132:Muscles / Q000378:metabolism; D012623:Seawater; D012867:Skin / Q000378:metabolism
D000977:Antiparasitic Agents; D007559:Ivermectin; C108024:emamectin benzoate